New Program Targets Women's Metabolism

A novel program is being introduced specifically for women experiencing perimenopause, focusing on muscle loss and metabolism after the age of 40. This initiative comes in response to the significant impact of GLP-1 medications like Ozempic and Wegovy on the weight loss market. The program aims to provide tailored support and interventions for women navigating the physiological changes associated with perimenopause, addressing concerns beyond general weight management.